Michael Sinclair - Aug 23, 2021 Form 4 Insider Report for OPIANT PHARMACEUTICALS, INC. (OPNT)

Role
Director, 10%+ Owner
Signature
/s/ Michael Sinclair
Stock symbol
OPNT
Transactions as of
Aug 23, 2021
Transactions value $
-$1,606,674
Form type
4
Date filed
8/25/2021, 04:38 PM
Next filing
Jun 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OPNT Common Stock, par value $0.001 per share Options Exercise $326K +65.1K +45.2% $5.00* 209K Aug 23, 2021 Direct
transaction OPNT Common Stock, par value $0.001 per share Sale -$1.07M -65.1K -31.13% $16.50 144K Aug 23, 2021 Direct F1
transaction OPNT Common Stock, par value $0.001 per share Options Exercise $173K +34.6K +24.02% $5.00* 179K Aug 24, 2021 Direct
transaction OPNT Common Stock, par value $0.001 per share Sale -$544K -34.6K -19.37% $15.71 144K Aug 24, 2021 Direct F2
transaction OPNT Common Stock, par value $0.001 per share Options Exercise $251K +50.3K +34.89% $5.00* 194K Aug 25, 2021 Direct
transaction OPNT Common Stock, par value $0.001 per share Sale -$738K -50.3K -25.87% $14.69 144K Aug 25, 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OPNT Options Options Exercise $0 -65.1K -43.42% $0.00 84.9K Aug 23, 2021 Common Stock, par value $0.001 per share 65.1K $5.00 Direct F4
transaction OPNT Options Options Exercise $0 -34.6K -40.77% $0.00 50.3K Aug 24, 2021 Common Stock, par value $0.001 per share 34.6K $5.00 Direct F4
transaction OPNT Options Options Exercise $0 -50.3K -100% $0.00* 0 Aug 25, 2021 Common Stock, par value $0.001 per share 50.3K $5.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $16.00 to $17.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed in multiple trades at prices ranging from $15.50 to $16.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $13.80 to $15.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 These options became exercisable on December 15, 2014 when Opiant Pharmaceuticals entered into a distribution, licensing, royalty, partnership, collaboration, or other significant transaction with respect to the opioid overdose reversal treatment with Adapt Pharma Operations Limited.